Cerebral Palsy
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
Drugs by status
Approved for this indication (5)
Phase 4 trials (22)
Phase 3 trials (14)
Phase 2 trials (15)
- metformin
- autologous cd133+ stem cells
- peripheral blood lymphocytes
- stem cells
- allogeneic adipose derived mesenchymal stem cell
- allogeneic cord blood
- autologous umbilical cord blood
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- cord blood hematopoietic stem cell
- cord blood stem cells
- sargramostim
- cenegermin-bkbj
- autologous hematopoietic stem cells
- udi-001
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (26)
- Medy-Tox
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Guangzhou Women and Children's Medical Center
- Aarhus University
- Harvard University
- Guangzhou Medical University
- Hospital Civil Juan I. Menchaca
- Northwestern University
- Norwegian University of Science and Technology
- Osaka University
- Seoul National University
- The Hospital of Vestfold
- Sunnaas Rehabilitation Hospital
- University Hospital of North Norway
- University of Guadalajara
- University of Bergen
- Yonsei University
- Columbia University
- Sathbhavana Brain Clinic
- University of California, Los Angeles
- University of Copenhagen
- Hebrew University
- University of Verona
- Government of Norway
- Elsass Foundation
- Columbia Irving Medical Center
Organization Involved with Phase 3 Indications (32)
- Shionogi
- Ipsen
- Allergan
- Hugel
- Merz
- Teva
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Maastricht University
- Cairo University
- University of London
- Kocaeli University
- Shaanxi Provincial People's Hospital
- Shriners Hospitals for Children
- Thomas Jefferson University
- University of Virginia
- Department of Clinical Research and Innovation
- GW Research
- Jiao Tong University
- University of Western Brittany
- University of Lyon
- King's Health Partners Clinical Trials Office
- Universidad Autonoma de Barcelona
- University of Nice Sophia Antipolis
- University of Alabama, Birmingham
- University of Paris
- Washington University in St. Louis
- Medtronic
- George Washington University
- Xi'an Medical University
- +2 more
Organization Involved with Phase 2 Indications (35)
- Elan Pharmaceuticals
- LG
- Stem Cells Arabia
- Swiss National Science Foundation
- Shahid Beheshti University of Medical Sciences
- Ain Shams University
- Alborz Medical University
- Duke University
- Hanyang University
- Hormozgan University of Medical Sciences
- Royan Institute
- Stanford University
- Swiss Neonatal Network
- Universidad Autonoma de Nuevo Leon
- University of Southern California
- University of Tehran
- University of Toronto
- Vinmec International Hospital
- University of Zurich
- Tel Aviv University
- Karolinska Institute
- Cha Medical University
- Chaitanya Hospital
- Government of Korea
- University of Texas at Houston
- The Marcus Foundation
- Cord Blood Registry, Inc.
- Danderyd Hospital AB.
- Let's Cure CP Foundation
- TIRR Foundation
- +5 more
Organization Involved with Phase 1 Indications (18)
- Acorda Therapeutics
- INC Research
- Guangdong Women and Children Hospital
- Kyung Hee University
- Mansoura University
- Monash University
- Neurogen Brain and Spine Institute
- University of Melbourne
- Fujian Medical University
- University Ramon Llull
- University of Queensland
- Association of Cerebral Palsy
- University of New South Wales
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Cerebral Palsy Alliance
- Cerebral Palsy Association
- Murdoch University
- R-Biopharm
Organization Involved with Other Experimental Indications (19)
- Chong Kun Dang Pharmaceutical
- Sung Kwang Medical Foundation
- Aljazeera Hospital
- University of New Mexico
- University of Nove de Julho
- University of Delaware
- National Taiwan University
- University of Ljubljana
- University of Gothenburg
- Yeungnam University
- Thrasher Research Fund
- Government of Taiwan
- University of Gloucestershire
- St Mary's University College
- Ankara Yildirim Beyazıt University
- The University of Texas, Dallas
- Anahuac University
- AMR KHALIL ORTHOPEDIC SURGERY CENTER
- PharmaHemp